A unique pain program is helping complex surgical patients wean off opioids safely and effectively, while offering alternative ways to cope with their pain and improve how they
Woodcliff Lake, NJ and Kenilworth, NJ, Aug. 16, 2018 – Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today
JERUSALEM & TARRYTOWN, N.Y.–(BUSINESS WIRE)–Aug. 16, 2018– Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a Phase
A Johns Hopkins expert panel of health care providers and patients have announced what is, to their knowledge, the nation’s first set of operation-specific opioid prescribing guidelines. The
WASHINGTON, Aug. 9, 2018 /PRNewswire/ — 60 Degrees Pharmaceuticals (60P) announced today the U.S. Food and Drug Administration (FDA) approval of Arakoda (tafenoquine) tablets for the prevention of
It started with a rolled ankle during a routine Army training exercise. Shannon Hubbard never imagined it was the prologue to one of the most debilitating pain conditions
The European Medicines Agency (EMA) said Thursday it is conducting a review of the health effects on patients of a widely used blood pressure medication recalled around the
Current research demonstrates that patients’ exposure to opioids following medical care has contributed to the nationwide addiction epidemic. An estimated 2.1 million Americans are reported to have an
On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a
Among convicted offenders, receiving methadone is associated with lower rates of death from external and non-external causes, according to new research published this week in PLOS Medicine by
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
